Opendata, web and dolomites

PAPRAT SIGNED

PAPRAT (Predictive Algorithm for Pre-Rheumatoid Arthritis Treatment). The new and most efficient multiple biomarkers-based system for an early selection of RA treatment intensity

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PAPRAT project word cloud

Explore the words cloud of the PAPRAT project. It provides you a very rough idea of what is the project "PAPRAT" about.

discerning    accuracy    rheumatoid    once    medium    45    treatment    personalized    antibodies    spent    combines    globally    demographical    patients    yearly    arthritis    burden    complete    genetic    biosimilars    pain    multiple       accurate    ageing    joints    calculate    efficient    few    unnecessary    outcome    index    aggressive    acpa    service    economic       difficult    algorithm    paprat    genomic    ra    validate    software    licensing    predictive    optimize    biomarker    bone    proper    administration    world    40    organs    protein    finished    blood    classify    severity    health    addressable    deterioration    bn    markers    drivers    genetics    prognosis    dmards    prognostics    reduce    epigenetic    3m    critical    suffering    start    continued    unclassified    anti    classifying    complications    launch    grow    total    biological    good    platform    spanish    remission    population    poorly    lack    market    disease    trl6    17    degenerative    designed    82    citrullinated    disability    therapy    clinical    combined    leave    medicine    rf    needing    variables    deformity    delays    prepare   

Project "PAPRAT" data sheet

The following table provides information about the project.

Coordinator
MAKING GENETICS S.L. 

Organization address
address: PLAZA CEIN 1, POLIGONO MOCHOLI, OFICINA R1.9, NOAIN
city: NOAIN
postcode: 31110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MAKING GENETICS S.L. ES (NOAIN) coordinator 50˙000.00

Map

 Project objective

Rheumatoid arthritis (RA) affects 1% of world population (17.6 M) and it is a relevant economic burden (€45 Bn spent yearly in Europe). It is a degenerative disease that affects bone health, cause joints’ deformity, impact other organs and cause disability. An early and personalized treatment can greatly improve its outcome, achieve remission and reduce pain, thus an accurate prognosis is critical for its efficient management. However, this is difficult for the lack of good prognosis factors (currently rheumatoid factor-RF or anti-citrullinated protein antibodies-ACPA), which at present are very few, poorly accurate and leave 40% of patients unclassified (suffering health complications due to an unnecessary aggressive treatment or from deterioration due to delays in proper treatment). Making Genetics is a Spanish start-up focused in personalized medicine through genomic approaches. We have designed and developed a prognostics test for RA based on a blood test and the use of our new PAPRAT algorithm, with 82.4% accuracy. PAPRAT is a multiple biomarker-based system capable of classifying pre-rheumatoid arthritis patients, discerning which will need a more aggressive treatment. It combines unique genomic markers (genetic and epigenetic), as well as clinical and demographical variables, to calculate a predictive index and classify patients’ RA severity as HIGH (needing early administration of a combined therapy with biological DMARDs) or LOW and MEDIUM (non-biological DMARDs are enough). It is at a TRL6 and now we aim to optimize it, further validate it, develop a software platform and prepare its market launch. RA is expected to grow by drivers such as an ageing population or the continued uptake of biosimilars, and we have currently a total addressable market of 17.6 M patients globally and of around 3M in Europe. We will offer a complete prognosis service, including the blood testing, as well as the licensing of our software platform once it is finished.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAPRAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PAPRAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More